MicroFluidics(MFLU.0B) Update-Reiterate Buy at $0.85
Microfluidics released earnings on Tuesday with good results: $4.5M in Q2 Revenue a 30% increase over the same quarter in 2009. Net Income of $143k compared to a loss of $177k in the same quarter of 2009.($396k before EBITA). Achieved a gross margin of 64%. Began shipping the LV1 low volume...
Summer Rally is Over-Risk is Off
Be thankful for the July rally that brought you 8-10% gains.It is time to protect your portfolio and play defense as market seasonality favors the bears from mid-August through mid-October. September can be the worse month so be patient for the year-end rally.To make matters worse this market...
After the FED: Value Found in Global Pharma Stocks
The market recovered from bigger losses with the S&P down 0.7%. The FED said economic growth will be modest and made two decisions for a neutral policy : taking money from mortgage securities to buy treasuries and keeping its balance sheet unchanged. This means money will not be drained...
Life Science Tools and Dx: Caliper(CALP) and Celera (CRA)Report Results
Two companies that have been restructured through M&A announced yesterday. Celera(CRA) was added to our model portfolio recently at 7, traded down 2% to $6.75 on missed guidance and a net loss of (.08) compared to a loss of 39 cents the same quarter of previous year. Revenue guidance was...
Model Portfolio:Life Science Tools and Dx
Q1 P Original Price % Return Q 2 P 8/2/10 % Recom 3/29/10 P Ret. Abaxis ABAX 26.8 2/2/09 15 79 21.2 20.7 30 Celera CRA 6.8 3/28/10 7 6.49 6.85 -2 Exact Sci EXAS UR 4.2 Genomic Health GHDX UR 12.6 13.1 Genoptix GXDX UR 17.2 18.13 GenProbe GPRO 48 2/2/09 45 7 46.3 45.9 5 Illumina ILMN 39 2/2/09...